Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05603754 · ClinicalTrials.gov registry record · Phase 3
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
A Phase 3 study, sponsored by Biosplice Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 496
- Enrollment target
NCT05603754 is a Phase 3 study that has completed, run by Biosplice Therapeutics. The registered enrollment target is 496 participants.
The verdict
NCT05603754, a Phase 3 study, has completed, sponsored by Biosplice Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 496 participants
- Enrollment target
Study Summary
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.
Interventions
- DRUG Placebo
- DRUG Lorecivivint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2024-02-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05603754
The ClinicalTrials.gov registry entry for NCT05603754 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05603754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05603754 about?
NCT05603754 is a clinical study titled "A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)". This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injec...
What is the current status of trial NCT05603754?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 496 participants. The study started on 2022-11-18. Estimated completion is 2024-02-20.
What interventions are being tested in trial NCT05603754?
The interventions under investigation include: Placebo (DRUG), Lorecivivint (DRUG).
Who is sponsoring clinical trial NCT05603754?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.